Abstract A011: OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signaling

Abstract Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell lymphomas (BCL). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCL, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCL cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a previously unrecognized tumor suppressor and uncover an OSTM1-PDE3B-cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability. Citation Format: Muhammad Usama. Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Yi Sun, Richard Lin, Christian Hinrichs, Francesco Bertoni, Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong. OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signaling [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A011.

Authors

Institutions

Publication Details

Journal
Blood Cancer Discovery
Published
2026-06-24
DOI
https://doi.org/10.1158/2643-3249.lymphoma26-a011
Primary Topic
Phosphodiesterase function and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract A011: OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signaling

Lynn Wang, Y Sun, Francesco Bertoni, Jianliang Shen et al.
Blood Cancer Discovery
Phosphodiesterase function and regulation
article

Abstract A011: OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signaling

Lynn Wang, Y Sun, Francesco Bertoni, Jianliang Shen, Jaeyong Jung, Namratha Sheshadri, Wei‐Xing Zong, Rongrong Li, Hassan Sajjad, Christian Hinrichs, Ping Xie, Richard Lin, Muhammad Usama. Tariq, Jean Vacher
article en

Abstract

Abstract Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell lymphomas (BCL). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCL, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCL cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a previously unrecognized tumor suppressor and uncover an OSTM1-PDE3B-cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability. Citation Format: Muhammad Usama. Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Yi Sun, Richard Lin, Christian Hinrichs, Francesco Bertoni, Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong. OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP-PKA-CREB signaling [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr A011.

Blood Cancer DiscoveryVol. 7(3_Supplement)
Rutgers, The State University of New Jersey (US), Fox Chase Cancer Center (US), Institute of Oncology Research (CH), Montreal Clinical Research Institute (CA), Stony Brook University (US)
Openalex Percentile: Top 11%
Phosphodiesterase function and regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.